Djamai et al. investigated the therapeutic potential of the LIMK1/2 inhibitor CEL_Amide (LIMKi) in FLT3-ITD-mutated (FLT3-ITD+) acute myeloid leukemia (AML). This evidence concerns the gene FLT3 and acute myeloid leukemia.